Telomere length and ApoE polymorphism in mild cognitive impairment, degenerative and vascular dementia
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND Clarifying the aetiology of dementia is of crucial importance in the management of patients as well as for research purposes but it is not always possible clinically. Therefore the identification of biological markers should complement clinical approaches. Telomere shortening is emerging as an important mechanism in vascular aging and the pathogenesis of hypertension and atherosclerosis. Thus, telomere length could be a potential candidate to accurately separate vascular from degenerative cognitive impairment. OBJECTIVES To evaluate the usefulness of telomere length alone or combined with ApoE polymorphism in diagnosing mild cognitive impairment (MCI) and in differentiating Alzheimer's disease (AD) from vascular (VaD) and mixed dementia (MD). METHODS Telomere length in peripheral blood lymphocytes was performed by flow cytometry in 439 patients (mean age, 85.1 years): 204 cognitively normal, 187 demented patients: 80 AD, 86 MD, and 21 with VaD; and 48 patients with MCI. Simple and multiple ordered logistic regressions were used to predict the risk of dementia from telomere length, ApoE polymorphism and age. RESULTS ApoEε4 was statistically associated with patients with dementia (p<0.001) compared to cognitively normal or MCI patients; but not with the aetiologies of dementia (AD, VaD and MD) (p=0.385). No significant differences in telomere length were found among patients with different aetiologies or severities of dementia. In the global model, the combination of telomere length and ApoE polymorphism did not confer a significantly higher dementia risk (OR=0.95, 95% CI=0.69-1.32; p=0.784) than APOEε4 alone (OR=2.12, 95% CI=1.15-3.9; p=0.016). CONCLUSION This longitudinal study in very old patients provided no evidence suggesting that telomere length alone could be used to distinguish between the different types of dementia or MCI, nor combined with the ApoE polymorphism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Welsh, K. A., Butters, N., Mohs, R. C., Beekly, D., Edland, S., Fillenbaum, G., & Heyman, A. (1994) · Neurology · doi:10.1212/wnl.44.4.609 · Cited by 951
Coon, K. D., Myers, A. J., Craig, D. W., Webster, J. A., Pearson, J. V., Lince, D. H., Zismann, V. L., Beach, T. G., Leung, D., Bryden, L., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0419 · Cited by 569
In vivo loss of telomeric repeats with age in humans
Lindsey, J., McGill, N. I., Lindsey, L. A., Green, D. K., & Cooke, H. J. (1991) · Mutation Research/DNAging · doi:10.1016/0921-8734(91)90032-7 · Cited by 463 · cited 1×
“Telomere length is emerging as an important mechanism in vascular aging and, consequently, in the pathogenesis of hypertension, atherosclerosis, and heart failure [2–7] and represents a potential biomarker.”
Telomere length in different tissues of elderly patients
Friedrich, U., Griese, E.-U., Schwab, M., Fritz, P., Thon, K.-P., & Klotz, U. (2000) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(00)00173-1 · Cited by 325 · cited 1×
“This is logical with respect to the accessibility of the patient's material and previous studies, which suggest that telomere length in blood, can be used as a surrogate marker for telomere length in other tissues [32].”
Shortened telomere length in white blood cells of patients with IDDM.
Jeanclos, E., Krolewski, A., Skurnick, J., Kimura, M., Aviv, H., Warram, J. H., & Aviv, A. (1998) · Diabetes · doi:10.2337/diabetes.47.3.482 · Cited by 217 · cited 1×
“Telomere length is emerging as an important mechanism in vascular aging and, consequently, in the pathogenesis of hypertension, atherosclerosis, and heart failure [2–7] and represents a potential biomarker.”
Cited by
Telomeres and early-life stress: an overview
Price, L. H., Kao, H.-T., Burgers, D. E., Carpenter, L. L., & Tyrka, A. R. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.025 · Cited by 339
Cellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
Meta-analysis of Telomere Length in Alzheimer’s Disease
Forero, D. A., González-Giraldo, Y., López-Quintero, C., Castro-Vega, L. J., Barreto, G. E., & Perry, G. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw053 · Cited by 229
“It was not possible to include two additional studies, which did not provide TL data (22,23) (Supplementary Figure S1).”
BackgroundFrom cellular senescence to Alzheimer’s disease: The role of telomere shortening
Boccardi, V., Pelini, L., Ercolani, S., Ruggiero, C., & Mecocci, P. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.04.003 · Cited by 121
Lin, J., Kroenke, C. H., Epel, E., Kenna, H. A., Wolkowitz, O. M., Blackburn, E., & Rasgon, N. L. (2011) · Brain Research · doi:10.1016/j.brainres.2010.10.033 · Cited by 86
Metadata
- Authors
- Zekry, D., Herrmann, F. R., Irminger-Finger, I., Graf, C., Genet, C., Vitale, A.-M., Michel, J.-P., Gold, G., & Krause, K.-H.
- Venue
- Journal of the Neurological Sciences
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 299
- Issue
- 1-2
- Pages
- 108-111
- ISSN
- 0022-510X (ISSN-L)
- OpenAlex
- W2004667370
- Cited by
- 54
- References
- 5
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Telomere length and ApoE polymorphism in mild cognitive impairment, degenerative and vascular dementia. https://app.cochat.ai/papers/10.1016/j.jns.2010.07.019
- The paper
- Zekry, D., Herrmann, F. R., Irminger-Finger, I., Graf, C., Genet, C., Vitale, A.-M., Michel, J.-P., Gold, G., & Krause, K.-H. (2010). Telomere length and ApoE polymorphism in mild cognitive impairment, degenerative and vascular dementia. Journal of the Neurological Sciences. https://doi.org/10.1016/j.jns.2010.07.019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.